No Risk of Heart Attack From Abacavir Seen By FDA

Federal drug safety reviewers have determined that there does not appear to be any link between side effects of abacavir, an HIV drug sold under the brand names Ziagen, Epzicom and Trizivir, and an increased risk of heart attacks. 

On Tuesday, the FDA issued an update on an ongoing safety review of abacavir, announcing that the agency had conducted a meta-analysis of 26 randomized clinical trials and found no association with increased risk of myocardial infarction, or heart attack.

Abacavir, which is the generic name for the medication Ziagen, is a potent nucleoside reverse transcriptase inhibitor used as an oral medication to treat AIDS and HIV. Other medications containing abacavir include Epzicom (abacavir and lamivudine) and Trizivir (abacavir, lamivudine and zidovudine).

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In the human body, abacavir converts into its active form, carbovir triphosphate, which is similar in form to deoxyguanosine triphosphate (dGTP), which is needed by HIV to synthesize DNA for self-replication. The enzyme reverse transcriptase mistakenly uses carbovir triphosphate instead of deoxyguanosine triphosphate to make DNA. This interferes with the enzyme’s activity and reduces the chances of successful replication of the virus. However, abacavir does not kill existing HIV nor is it a cure for HIV. It can be used alone or with other anti-HIV drugs.

The FDA began conducting its review of abacavir after a study of HIV drugs using data collected through 2007 suggested the drugs Videx (didanosine) and abacavir increased heart attack risk. Both are members of a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

The randomized trials looked at a total of 9,868 subjects either on abacavir or a similar drug that did not contain abacavir. The FDA found a total of 46 reported heart attacks; 24 suffered by the group taking abacavir and 22 suffered by the group taking another drug. The FDA said the difference was statistically insignificant.

In July 2008, the FDA issued an abacavir health alert, warning that some users may suffer abacavir hypersensitivity. The use of medications containing abacavir is not being recommended for patients who test positive for the HLA-B*5701 allele, and the FDA indicates they should only be considered under exceptional circumstances when the potential benefit outweighs the risk.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted today)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted yesterday)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.

Master Baby Food Lawsuit Filed in MDL Outlines How Toxic Metals Caused Autism, ADHD in Children
Master Baby Food Lawsuit Filed in MDL Outlines How Toxic Metals Caused Autism, ADHD in Children (Posted 4 days ago)

Plaintiffs have submitted a baby food lawsuit Master Complaint that is expected to streamline the filing of lawsuits alleging that toxic heavy metals in Beech-Nut, Gerber, Hain and Nurture products caused ADHD, autism and other developmental disorders.